Andrew Mancini, PhD profile page

Andrew Mancini, PhD, is a cell engineering scientist and corporate development professional with a background in both technical research and business strategy in the cell therapy space. He began his tenure at MaxCyte, Inc. as a field scientist, working closely with cell therapy developers to optimize their gene editing workflows. He later transitioned to corporate development, where he now serves as Senior Corporate Development Manager. In his current role, Dr. Mancini leads both scientific partnerships and M&A initiatives as part of MaxCyte’s corporate development team. He works with academic and commercial cell therapy developers to assess and structure strategic collaborations, leveraging his technical expertise in cell engineering and gene editing to drive deal-making. His responsibilities include identifying and evaluating partnership and acquisition opportunities, conducting due diligence, and supporting MaxCyte’s corporate strategy, marketing, and business development efforts. Prior to his work at MaxCyte, Dr. Mancini earned his PhD in Biomedical Sciences from the University of California, San Francisco (UCSF), where he specialized in primary cell gene editing, investigating the role of TERT mutations in glioblastoma. He then completed his postdoctoral training in Molecular Oncology at Genentech, further advancing his expertise in genome engineering and translational research.